Javascript must be enabled to continue!
Analysis of EGFR gene mutation in patients with Non-Small cell lung cancer in Hue Central hospital
View through CrossRef
Objective: To analyze the EGFR mutation index on the cancer blocs of the patients with non - small cell lung cancer (NSCLC) at the Department of Pathology - Hue Central Hospital.
Subjects and methods: A prospective, cross-sectional descriptive study of 227 patients with advanced, metastatic non - small cell lung cancer who were mutated in the EGFR gene. The study were carried out on the cancer parrafin blocs stored in Pathology Department, Hue Central Hospital.
Results: Mean age 58.29 ± 9.36 years old, male/female ratio 1.58. Histopathology is mainly adenocarcinoma: 96%, squamous epithelium: 0.9%, large cell: 3.1%. EGFR mutation rate positive 38.3%, negative: 61.7%. The rate of positive EGFR mutations in women: (53.4%) is higher than in men: (28.8%). The rate of positive EGFR mutations in the smoking group: (24.4%), insignificant smoking: (32.8%), the non - smoking group (56.6%). The cases of patients carrying mutations in EGFR gene have 50.6% of LREA deletion mutations in exon 19; 40.23% are L858R substitution mutations in exon 21; 3.45% are G719X mutations and 2.3% are G719S mutations in exon 18; 1.14% are Q787 mutations in exon 20; 1.14% are double mutations S768I + V769L in exon 20 and T790M + L858R in exons 20 and 21.
Conclusion: The rate of EGFR gene mutation in NSCLC patients was 38.3%, higher in women than in men and especially high in non - smokers or non - smokers, the difference was statistically significant with p. < 0.05. The most common TKI - sensitive mutations include deletion mutations in exon 19 and substitution mutations in exon 21 (accounting for more than 90%), a percentage less than 5% are mutations.
Title: Analysis of EGFR gene mutation in patients with Non-Small cell lung cancer in Hue Central hospital
Description:
Objective: To analyze the EGFR mutation index on the cancer blocs of the patients with non - small cell lung cancer (NSCLC) at the Department of Pathology - Hue Central Hospital.
Subjects and methods: A prospective, cross-sectional descriptive study of 227 patients with advanced, metastatic non - small cell lung cancer who were mutated in the EGFR gene.
The study were carried out on the cancer parrafin blocs stored in Pathology Department, Hue Central Hospital.
Results: Mean age 58.
29 ± 9.
36 years old, male/female ratio 1.
58.
Histopathology is mainly adenocarcinoma: 96%, squamous epithelium: 0.
9%, large cell: 3.
1%.
EGFR mutation rate positive 38.
3%, negative: 61.
7%.
The rate of positive EGFR mutations in women: (53.
4%) is higher than in men: (28.
8%).
The rate of positive EGFR mutations in the smoking group: (24.
4%), insignificant smoking: (32.
8%), the non - smoking group (56.
6%).
The cases of patients carrying mutations in EGFR gene have 50.
6% of LREA deletion mutations in exon 19; 40.
23% are L858R substitution mutations in exon 21; 3.
45% are G719X mutations and 2.
3% are G719S mutations in exon 18; 1.
14% are Q787 mutations in exon 20; 1.
14% are double mutations S768I + V769L in exon 20 and T790M + L858R in exons 20 and 21.
Conclusion: The rate of EGFR gene mutation in NSCLC patients was 38.
3%, higher in women than in men and especially high in non - smokers or non - smokers, the difference was statistically significant with p.
< 0.
05.
The most common TKI - sensitive mutations include deletion mutations in exon 19 and substitution mutations in exon 21 (accounting for more than 90%), a percentage less than 5% are mutations.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract 2205: Identification of potential biomarker related to EGFR mutation by functional proteome profiling in primary non-small cell lung cancer
Abstract
Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers which the leading cause of cancer-related death worldwide. Recently, epide...
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract
Purpose: Advanced stage lung adenocarcinoma patients with activating EGFR mutation have better survival result after EGFR tyrosine kinase inhibitor develope...
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract
BACKGROUND
Epidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance i...
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
It is indisputable that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) prolong progression-free survival in non-small-cell lung cancer (NSCLC) patients ...
Abstract 2609: Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival
Abstract 2609: Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival
Abstract
Purpose: EGFR tyrosine kinase inhibitor (EGFR TKI) was approved as a first line treatment for EGFR mutant lung adenocarcinoma (LADC) with advanced stage. YA...

